X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (75) 75
index medicus (63) 63
hematology (60) 60
middle aged (44) 44
aged (42) 42
female (41) 41
male (41) 41
adult (38) 38
multiple myeloma (38) 38
multiple myeloma - drug therapy (35) 35
oncology (28) 28
treatment outcome (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (24) 24
hematology, oncology and palliative medicine (23) 23
bortezomib (22) 22
abridged index medicus (20) 20
aged, 80 and over (19) 19
multiple myeloma - pathology (17) 17
therapy (17) 17
dexamethasone (15) 15
disease-free survival (15) 15
stem-cell transplantation (15) 15
transplantation (15) 15
animals (14) 14
cancer (14) 14
drug resistance, neoplasm (14) 14
survival (14) 14
thalidomide - administration & dosage (14) 14
recurrence (13) 13
thalidomide (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
multiple myeloma - therapy (12) 12
antineoplastic agents - therapeutic use (11) 11
drug therapy (11) 11
multiple myeloma - mortality (11) 11
prognosis (11) 11
survival analysis (11) 11
thalidomide - analogs & derivatives (11) 11
dexamethasone - administration & dosage (10) 10
immunology (10) 10
lenalidomide (10) 10
multiple myeloma - genetics (10) 10
multiple myeloma - metabolism (10) 10
patient outcomes (10) 10
transplantation, autologous (10) 10
busulfan - administration & dosage (9) 9
care and treatment (9) 9
cell line, tumor (9) 9
chemotherapy (9) 9
versus-host-disease (9) 9
vidarabine - administration & dosage (9) 9
vidarabine - analogs & derivatives (9) 9
busulfan (8) 8
combined modality therapy (8) 8
hematopoietic stem cell transplantation - methods (8) 8
prednisone - administration & dosage (8) 8
survival rate (8) 8
antibodies, monoclonal - administration & dosage (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
apoptosis (7) 7
carfilzomib (7) 7
clinical trials and observations (7) 7
cyclophosphamide (7) 7
elderly-patients (7) 7
melphalan - administration & dosage (7) 7
mice (7) 7
retrospective studies (7) 7
antineoplastic agents - pharmacology (6) 6
antineoplastic combined chemotherapy protocols (6) 6
article (6) 6
clinical trials (6) 6
daratumumab (6) 6
follow-up studies (6) 6
kaplan-meier estimate (6) 6
lenalidomide plus dexamethasone (6) 6
medicine, general & internal (6) 6
melphalan (6) 6
multiple myeloma - diagnosis (6) 6
myeloma (6) 6
prednisone (6) 6
quality of life (6) 6
research (6) 6
salvage therapy (6) 6
stem cell transplantation (6) 6
stem cells (6) 6
acute myelogenous leukemia (5) 5
adolescent (5) 5
antineoplastic agents - adverse effects (5) 5
cell proliferation (5) 5
hematologic neoplasms - therapy (5) 5
hematopoietic stem cell transplantation (5) 5
lymphoid neoplasia (5) 5
mice, scid (5) 5
neoplasm recurrence, local - drug therapy (5) 5
neoplasm staging (5) 5
prospective studies (5) 5
proteasome inhibitors (5) 5
risk (5) 5
safety (5) 5
thalidomide - adverse effects (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1551 - 1560
Summary Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs.... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | RISK | MULTICENTER | THERAPY | ELOTUZUMAB | Drug Administration Schedule | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Spain | Canada | Disease-Free Survival | Multiple Myeloma - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Drugs | Medical colleges | Biological products | Multiple myeloma | Monoclonal antibodies | Product development | Lymphomas | Drug therapy | Care and treatment | Analysis | Studies | Protease inhibitors | Hematology | Stem cells | Cytotoxicity | Patients | Drug dosages | Slopes | Therapy | Schedules | Intravenous administration | Stem cell transplantation | Transplantation | Drug screening | Immunosuppressive agents | Randomization | CD38 antigen | Autografts | Anemia | Immunomodulation | Research & development--R&D | FDA approval | Survival | Proteasome inhibitors | Asthma | Refractory materials | Inhibitors | Interactive systems | Response rates
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2016, Volume 375, Issue 14, pp. 1319 - 1331
Journal Article
Blood, ISSN 0006-4971, 04/2017, Volume 129, Issue 16, pp. 2208 - 2209
Journal Article
Current Cancer Drug Targets, ISSN 1568-0096, 2012, Volume 12, Issue 7, pp. 776 - 796
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 906 - 917
Journal Article
Blood, ISSN 0006-4971, 12/2011, Volume 118, Issue 24, pp. 6368 - 6379
Chromosomal instability is a defining feature of clonal myeloma plasma cells that results in the perpetual accumulation of genomic aberrations. In addition to... 
POLY(ADP-RIBOSE) POLYMERASE | MAINTENANCE | REPAIR | INSTABILITY | DNA-DAMAGE RESPONSE | DOUBLE-STRAND BREAKS | CLASSIFICATION | MECHANISMS | HOMOLOGOUS RECOMBINATION | HEMATOLOGY | MAMMALIAN-CELLS | Humans | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Proteasome Endopeptidase Complex | RNA, Messenger - metabolism | Enzyme Inhibitors - administration & dosage | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | BRCA1 Protein - metabolism | Adult | Antineoplastic Agents - pharmacology | Boronic Acids - administration & dosage | Gene Expression Regulation, Neoplastic - drug effects | Enzyme Inhibitors - adverse effects | Rad51 Recombinase - metabolism | DNA Repair - drug effects | Bortezomib | Rad51 Recombinase - genetics | Cells, Cultured | Enzyme Inhibitors - pharmacology | Mice, SCID | Multiple Myeloma - metabolism | Enzyme Inhibitors - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Multiple Myeloma - pathology | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Survival Analysis | Cell Line, Tumor | Mice | Proteasome Inhibitors | Pyrazines - pharmacology | Boronic Acids - pharmacology
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1831 - 1831
Background: Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action. The intravenous... 
Journal Article
Haematologica, ISSN 0390-6078, 06/2019, p. haematol.2019.217448
The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4459 - 4459
Abstract Background: A renewed interest in immune and cellular based therapeutics in multiple myeloma was recently fueled by the development of CD38 targeting... 
Journal Article
Blood, ISSN 0006-4971, 2014, Volume 124, Issue 12, pp. 1873 - 1879
Journal Article